-+ 0.00%
-+ 0.00%
-+ 0.00%

Ionis Q3 net loss narrows 15% to $110 million; Q3 revenue rises 55% to $243 million

PUBT·11/09/2026 12:06:54
Listen to the news
Ionis Q3 net loss narrows 15% to $110 million; Q3 revenue rises 55% to $243 million
  • Ionis Pharmaceuticals’ third-quarter 2026 net loss narrowed 15% year over year to $110 million.
  • Revenue climbed 55% year over year to $243 million, supported by increased commercial revenue and substantial partnership R&D revenue.
  • The 2026 TRYNGOLZA outlook was cut to approximately $50 million following a slower-than-expected launch ramp.
  • ZANVASTRO’s launch is underway, with the first patients receiving commercial treatment for Alexander disease.
  • Full-year 2026 total revenue guidance remained unchanged at $875 million-$900 million.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ionis Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202611090700BIZWIRE_USPR_____20261109_BW740265) on November 09, 2026, and is solely responsible for the information contained therein.